CYP3A4酶相关的临床药物相互作用

摘要/Abstract

摘要： 目的为CYP3A4酶的强抑制剂、强诱导剂的合理使用提供参考。方法查阅国内外相关文献，对CYP3A4酶强抑制剂、强诱导剂相关的临床药物相互作用研究及案例进行归纳和总结。结果 CYP3A4酶强抑制剂克拉霉素、蛋白酶抑制剂、三唑类抗真菌药等的临床药物相互作用报道较多，特别是与钙通道阻滞剂、他汀类药物、激素类药物、他克莫司等；强诱导剂利福平、卡马西平、苯妥英等的临床药物相互作用也有报道，如与口服避孕药、他克莫司、替格瑞洛等。结论临床应用CYP3A4酶强抑制剂、强诱导剂时需注意其对CYP3A4底物的影响，及时调整用药方案。

关键词: CYP3A4酶, 强抑制剂, 强诱导剂, 药物相互作用

Abstract: Objective To provide reference for rational use of strong inhibitors and strong inducers of CYP3A4 enzyme. Methods The related literatures at home and abroad with clinical research or case report about clinical drug interactions related to strong inhibitors and strong inducers of CYP3A4 enzyme were consulted and summarized. Results There are many clinical reports about strong inhibitors of CYP3A4 enzyme such as calcium channel blockers, clarithromycin, protease inhibitors and triazole antifungal agents particularly with statins, hormone drugs, tacrolimus, etc. There are also some clinical reports about strong inducers of CYP3A4 enzyme such as rifampin, carbamazepine and phenytoin with oral contraceptives, tacrolimus, ticagrelor, etc. Conclusion When strong inhibitors or strong inducers of CYP3A4 enzyme were used, attentions must be paid to their impact on CYP3A4 substrate, and regimen must be adjusted timely.

Key words: Key words：CYP3A4 enzyme, strong inhibitor, strong inducer, drug interaction

中图分类号:

R969.2

吴华,. CYP3A4酶相关的临床药物相互作用[J]. 中国药物警戒, 2016, 13(5): 286-290.

WU Hua . Clinical Drug Interactions Related to CYP3A4 Enzyme[J]. Chinese Journal of Pharmacovigilance, 2016, 13(5): 286-290.

参考文献

[1] Krau S D. Cytochrome p450, part 1:what nurses really need to know[J]. Nurs Clin North Am, 2013, 48(4):671-680.
[2] Sevrioukova I F, Poulos T L. Current Approaches for Investigating and Predicting Cytochrome P450 3A4-Ligand Interactions[J]. Adv Exp Med Biol, 2015, 851:83-105.
[3] FDA. Drug Development and Drug Interactions: Table of Substrates,Inhibitors and Inducers[EB/OL].(2011-07-28)[2015-10-10]. http://www.fda.gov/Drugs/Development Approval Process/Development Resources/Drug Interactions Labeling/ucm093664.htm#4.
[4] Wright A J, Gomes T, Mamdani M M, et al. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers[J]. CMAJ, 2011, 183(3):303-307.
[5] Gandhi S, Fleet J L, Bailey D G, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury[J]. JAMA, 2013, 310(23):2544-2553.
[6] Patel A M, Shariff S, Bailey D G, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study[J]. Ann Intern Med, 2013, 158(12):869-876.
[7] Li D Q, Kim R, McArthur E, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4[J]. CMAJ, 2015,187(3):174-180.
[8] Fallah A, Deep M, Smallwood D, et al. Life-threatening rhabdomyolysis following the interaction of two commonly prescribed medications: a case study[J]. Australas Med J, 2013, 6(3):112-114.
[9] 熊贤兵,李刚,罗文艳,等.1例辛伐他汀联用罗红霉素致横纹肌溶解患者的药学监护[J].中南药学, 2015,13(6):660-662.
[10] Mishra A, Pandya H V, Dave N, et al. A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin[J]. Indian J Pharmacol, 2014, 46(5):547-548.
[11] Horton R, Barber C. Opioid-induced respiratory depression resulting from transdermal fentanyl-clarithromycin drug interaction in a patient with advanced COPD[J]. J Pain Symptom Manage, 2009, 37(6):e2-5.
[12] Van der Velden W, Huussen J, Ter Laak H, et al. Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin[J]. Neth J Med, 2008, 66(5):204-206.
[13] Hung I F, Wu A K, Cheng V C, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study[J]. Clin Infect Dis, 2005, 41(3):291-300.
[14] Parissis H, Gould K, Dark J. Dangerous drug interactions leading to hemolytic uremic syndrome following lung transplantation[J]. J Cardiothorac Surg, 2010, 5:70.
[15] Schulz-Du Bois C, Schulz-Du Bois A C, Bewig B, et al. Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine[J]. Pharmacopsychiatry, 2008, 41(6): 258-259.
[16] 李坤艳,李焕德,程泽能,等.治疗剂量奎硫平与红霉素体内相互作用[J].中南药学, 2005, 3(4):240-242.
[17] Senthilkumaran S, Subramanian P T. Prolonged sedation related to erythromycin and midazolam interaction: a word of caution[J]. Indian Pediatr, 2011, 48(11):909.
[18] Watkins J L, Atkinson B J, Pagliaro L C. Rhabdomyolysis in a Prostate Cancer Patient Taking Ketoconazole and Simvastatin: Case Report and Review of the Literature[J].Ann Pharmacother, 2011, 45(2):e9.
[19] Tailor S A, Gupta A K, Walker S E, et al. Peripheral edema due to nifedipine-itraconazole interaction: a case report[J].Arch Dermatol, 1996, 132(3):350-352.
[20] Neuvonen P J, Suhonen R. Itraconazole interacts with felodipine[J]. J Am Acad Dermatol, 1995, 33(1):134-135.
[21] Crommentuyn K M, Mulder J W, Sparidans R W, et al. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis[J]. Clin Infect Dis, 2004, 38(8):e73-75.
[22] Blondin M C, Beauregard H, Serri O. Iatrogenic Cushing syndrome in patients receiving inhaled budesonide and itraconazole or ritonavir:two cases and literature review[J]. Endocr Pract, 2013, 19(6):e138-141.
[23] 王超,张弋.肝移植患者中伏立康唑与他克莫司药物相互作用病例分析[J].中国药房, 2014, 25(2):165-168.
[24] 黄翠丽,郭代红,朱曼,等.从1例肾移植术后肺部感染患者探讨伏立康唑与他克莫司的药物相互作用[J].中国药物应用与监测, 2014, 11(5):291-293.
[25] 曹伟,王祥慧,徐达,等.临床药师参与肾移植后肺部感染患者的药物治疗实践[J].中国临床药学杂志,2013,22(6):369-372.
[26] 张征,刘丽宏.临床药师对1例肾移植患者的药学服务药品评价[J]. 2013,10(22):39-41.
[27] Lecefel C, Eloy P, Chauvin B,et al. Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient[J]. J Clin Pharm Ther, 2015,40(1):119-120.
[28] Jones W, Chastain C A, Wright P W. Iatrogenic cushing syndrome secondary to a probable interaction between voriconazole and budesonide[J]. Pharmacotherapy, 2014, 34(7):e116-119.
[29] Gambillara E, Laffitte E, Widmer N, et al. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia[J]. Dermatology, 2005, 211(4): 363-365.
[30] Eiden C, Palenzuela G, Hillaire-Buys D, et al. Posaconazole-increased vincristine neurotoxicity in a child: a case report[J]. J Pediatr Hematol Oncol, 2009, 31(4):292-295.
[31] Pilmis B, Coignard-Biehler H, Jullien V,et al. Iatrogenic Cushing’s syndrome induced by posaconazole[J]. Antimicrob Agents Chemother, 2013, 57(11):5727-5728.
[32] 姚瑶,胡卓汉.CYP3A4介导的HIV-1蛋白酶抑制剂的增效作用[J].中国新药杂志, 2010,19(13):1124-1127.
[33] Brayer S W, Reddy K R. Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy[J]. Expert Rev Gastroenterol Hepatol,2015,9(5):547-558.
[34] Laura Dickinson, Alan Winston, Marta Boffito,et al. Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach[J]. J Int AIDS Soc, 2014,17(4Suppl 3): 19586.
[35] Avihingsanon A, Ramautarsing R A, Suwanpimolkul G, et al. Ergotism in Thailand caused by increased access to antiretroviral drugs: a global warning[J]. Top Antivir Med, 2014, 21(5):165-168.
[36] Epperla N, McKiernan F. Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone[J]. Springerplus, 2015, 4:455.
[37] Schwarze-Zander C, Klingmüller D, Klümper J, et al. Triamcinolone and ritonavir leading to drug-induced Cushing syndrome and adrenal suppression: description of a new case and review of the literature[J]. Infection, 2013, 41(6):1183-1187.
[38] Tsiattalos A S, Patel A. Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio: a case report[J]. J Med Case Rep, 2014, 8:433.
[39] Hammond K P, Nielsen C, Linnebur S A, et al. Priapism induced by boceprevir-CYP3A4 inhibition and α-adrenergic blockade: case report[J]. Clin Infect Dis, 2014 , 58(1):e35-38.
[40] Curran A, Guiu J M, Ribera E, et al. Darunavir and telaprevir drug interaction: total and unbound plasma concentrations in HIV/HCV-coinfected patients with cirrhosis[J]. J Antimicrob Chemother, 2014, 69(5):1434-1436.
[41] Baneyx G, Parrott N, Meille C, et al. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration[J]. Eur J Pharm Sci, 2014, 56:1-15.
[42] Krau S D. Cytochrome p450 part 3: drug interactions: essential concepts and considerations[J]. Nurs Clin North Am, 2013,48(4):697-706.
[43] Bhaloo S, Prasad G V. Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report[J]. Transplant Proc, 2003, 35(7):2449-2451.
[44] Decloedt E H, McIlleron H, Smith P, et al. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets[J]. Antimicrob Agents Chemother,2011, 55(7):3195-3200.
[45] 陈旭丽,王金明,杨赛成,等.利福平降低硝苯地平降压效果的案例分析[J].实用药物与临床, 2014,17(12):1596-1597.
[46] Radakovi? B, Goldstajn M S. Ectopic pregnancy as contraceptive failure in patient with epilepsy[J]. Coll Antropol, 2012, 36(4):1475-1476.
[47] Hugen P W, Burger D M, Brinkman K, et al. Carbamazepine--indinavir interaction causes antiretroviral therapy failure[J]. Ann Pharmacother, 2000, 34(4):465-470.
[48] Nickl-Jockschat T, Paulzen M, Schneider F, et al. Drug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepine[J]. Clin Neuropharmacol, 2009, 32(1):55.
[49] Yasui-Furukori N, Tateishi T. Carbamazepine decreases antihypertensive effect of nilvadipine[J]. J Clin Pharmacol, 2002, 42(1):100-103.
[50] Wada K, Takada M, Sakai M, et al. Drug interaction between tacrolimus and carbamazepine in a Japanese heart transplant recipient:a case report[J]. J Heart Lung Transplant, 2009, 28(4):409-411.
[51] Wada K, Takada M, Ueda T, et al. Drug interactions between tacrolimus and phenytoin in Japanese heart transplant recipients: 2 case reports[J]. Int J Clin Pharmacol Ther, 2007, 45(9):524-528.
[52] Spak C W, Dhanireddy S, Kosel B W. Clinical interaction between efavirenz and phenytoin[J]. AIDS, 2008, 22(1):164-165.
[53] Chowdhury L, Laha A, Chaudhuri T, et al. Chronic phenytoin therapy-induced vecuronium resistance[J]. Indian J Pharmacol, 2011, 43(2):214-215.
[54] 马伟斌.抗癫痫药联用对肝药酶的诱导效应[J].现代实用医学,2011, 23(6):711-712.
[55] Hayashi T, Higuchi H, Tomoyasu Y, et al. Effect of carbamazepine or phenytoin therapy on blood level of intravenously administered midazolam: a prospective cohort study[J]. J Anesth, 2016, 30(1):166-169.
[56] Weeks P, Sieg A, Vahdat K, et al. Improved ticagrelor antiplatelet effect on discontinuation of phenytoin[J]. Ann Pharmacother, 2014, 48(5):644-647.